Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical studies on recurrent prostatic cancer].

K Suzuki1, T Nakamura, N Kato

  • 1Department of Urology, Tatebayashi Kosei Hospital, Gunma.

Hinyokika Kiyo. Acta Urologica Japonica
|June 1, 1991
PubMed
Summary

Prostatic cancer patients responding to hormone therapy may experience recurrence. Stage D2 patients and those with higher-grade tumors face earlier recurrence, impacting survival rates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intervention of somatic mutational events in vivo by a germline defect at the adenine phosphoribosyltransferase locus.

Human genetics·1997
Same author

[Effects of alcohol on urate metabolism].

Nihon rinsho. Japanese journal of clinical medicine·1997
Same author

[A case report of renal cell carcinoma with bilateral adrenal metastases].

Hinyokika kiyo. Acta urologica Japonica·1997
Same author

An asymptomatic germline missense base substitution in the hypoxanthine phosphoribosyltransferase (HPRT) gene that reduces the amount of enzyme in humans.

Human genetics·1997
Same author

Generation and molecular characterisation of monoclonal IgG4 rheumatoid factor from a patient with rheumatoid arthritis.

Annals of the rheumatic diseases·1997
Same author

[How to select and use urate lowering agents for hyperuricemia].

Nihon rinsho. Japanese journal of clinical medicine·1996

Area of Science:

  • Oncology
  • Urology

Context:

  • Hormone-based therapies are a cornerstone in managing advanced prostatic cancer.
  • Understanding recurrence patterns is crucial for optimizing treatment strategies and patient outcomes.

Purpose:

  • To analyze recurrence patterns and survival rates in prostatic cancer patients treated with hormone-based therapy.
  • To identify clinical and pathological factors associated with earlier recurrence.

Summary:

  • A study of 114 prostatic cancer patients (1977-1989) found 99 responded to initial hormone therapy, with 28 experiencing recurrence.
  • Stage D2 patients exhibited significantly earlier recurrence (15.6 months) compared to earlier stages (B2, C, D1).
  • Histological grade did not significantly impact recurrence timing, though higher-grade tumors showed a tendency for recurrence upon pathological examination. Recurrence modes included new lesions and elevated tumor markers.

Related Experiment Videos

Impact:

  • Stage D2 prostatic cancer patients require closer monitoring due to significantly earlier recurrence.
  • Findings highlight the need for advanced treatment strategies for recurrent prostatic cancer, as multimodal therapy showed limited response rates (11% PR, 14.3% NC).
  • Survival rates post-recurrence are considerably lower (49.3% at 1 year, 12.5% at 3 years) than post-initial treatment (51.5% at 3 years, 31.2% at 5 years).